- Home
- NTIP vs FEMY Comparison
NTIP vs FEMY Comparison
Compare NTIP & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- FEMY
- Stock Information
- Founded
- NTIP 1990
- FEMY 2004
- Country
- NTIP United States
- FEMY United States
- Employees
- NTIP N/A
- FEMY N/A
- Industry
- NTIP Multi-Sector Companies
- FEMY Medical/Dental Instruments
- Sector
- NTIP Miscellaneous
- FEMY Health Care
- Exchange
- NTIP Nasdaq
- FEMY Nasdaq
- Market Cap
- NTIP 28.6M
- FEMY 31.9M
- IPO Year
- NTIP 1998
- FEMY 2021
- Fundamental
- Price
- NTIP $1.22
- FEMY $0.95
- Analyst Decision
- NTIP
- FEMY Strong Buy
- Analyst Count
- NTIP 0
- FEMY 3
- Target Price
- NTIP N/A
- FEMY $8.67
- AVG Volume (30 Days)
- NTIP 13.9K
- FEMY 369.9K
- Earning Date
- NTIP 08-11-2025
- FEMY 08-07-2025
- Dividend Yield
- NTIP 8.00%
- FEMY N/A
- EPS Growth
- NTIP N/A
- FEMY N/A
- EPS
- NTIP N/A
- FEMY N/A
- Revenue
- NTIP $250,000.00
- FEMY $1,699,232.00
- Revenue This Year
- NTIP N/A
- FEMY $231.84
- Revenue Next Year
- NTIP N/A
- FEMY $245.28
- P/E Ratio
- NTIP N/A
- FEMY N/A
- Revenue Growth
- NTIP N/A
- FEMY 61.97
- 52 Week Low
- NTIP $1.16
- FEMY $0.69
- 52 Week High
- NTIP $1.78
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- NTIP 49.11
- FEMY 48.09
- Support Level
- NTIP $1.20
- FEMY $0.91
- Resistance Level
- NTIP $1.30
- FEMY $0.95
- Average True Range (ATR)
- NTIP 0.05
- FEMY 0.06
- MACD
- NTIP -0.00
- FEMY 0.01
- Stochastic Oscillator
- NTIP 49.29
- FEMY 31.16
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.